Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Toll like receptor 5 agonist - Connext

Next Previous
Drug Profile

Toll like receptor 5 agonist - Connext

Alternative Names: Advanced entolimod; CNT-101; CNT-102; KMRC011; Korea Medical Radiation Countermeasure 011

Latest Information Update: 28 May 2025

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Korea Institute of Industrial Technology
  • Developer Connext; iNtRON Biotechnology
  • Class Anti-inflammatories; Antineoplastics; Immunotherapies; Peptides; Radioprotectives
  • Mechanism of Action Apoptosis inhibitors; NF-kappa B modulators; Toll-like receptor 5 agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes
  • Available For Licensing Yes - Cancer; Graft-versus-host disease; Stomatitis

Highest Development Phases

  • Phase I Graft-versus-host disease; Mucositis; Stomatitis
  • Preclinical Cancer
  • No development reported Acute radiation syndrome

Most Recent Events

  • 28 May 2025 No recent reports of development identified for phase-I development in Acute-radiation-syndrome(In volunteers) in South Korea (IM, Injection)
  • 29 Apr 2024 Phase-I clinical trials in Mucositis (Prevention) (Parenteral) (Connext pipeline; April 2024)
  • 27 Nov 2023 Phase-I clinical trials in Stomatitis in South Korea (Parenteral) before November 2023 (Connext Pipeline, November 2023)

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top